MLYS · NASDAQ · Biotechnology

Mineralys Therapeutics (MLYS)

Develops lorundrostat for uncontrolled hypertension and related cardiorenal conditions.

$29.03
Pre-market−0.02 (−0.07%)
At close$29.05(+13.61%)

Something off on this page? Send us feedback.

Next report
Nov 9, 2026
in 67 days
EPS estimate
−$0.53
Revenue estimate
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Feb '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.98−$0.79−$0.66−$0.52−$0.40−$0.47−$2.85Pending
Estimate−$1.00−$1.02−$0.78−$0.66−$0.52−$0.51−$0.55−$0.53
Surprise+2.0%+22.5%+15.4%+21.2%+22.5%+7.8%−419.5%

RevenueReportedEstimate

Feb '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
ReportedPending
Estimate
Surprise

History

DateEstimateReportedSurprise
Nov 2026−$0.53
Aug 2026−$0.55−$2.85−419.5%
May 2026−$0.51−$0.47+7.8%
Mar 2026−$0.52−$0.40+22.5%
Nov 2025−$0.66−$0.52+21.2%

The latest year is open to everyone — the 15 quarters behind it read with an account.

Sign in
Aug 2025
May 2025
Feb 2025
Nov 2024
Aug 2024
May 2024
Mar 2024
Nov 2023
Aug 2023
May 2023
Mar 2023
Feb 2023
Jun 2022
Mar 2022
Dec 2021
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Nov 9, 2026−$0.53
Aug 12, 2026−$0.55−$2.85−419.5%−3.6%
May 6, 2026−$0.51−$0.47+7.8%−2.6%
Mar 12, 2026−$0.52−$0.40+22.5%−3.0%
Nov 10, 2025−$0.66−$0.52+21.2%+5.9%

The latest year is open to everyone — the 15 quarters behind it read with an account.

Sign in
Aug 12, 2025
May 12, 2025
Feb 12, 2025
Nov 11, 2024
Aug 13, 2024
May 9, 2024
Mar 21, 2024
Nov 7, 2023
Aug 7, 2023
May 15, 2023
Mar 15, 2023
Feb 10, 2023
Jun 30, 2022
Mar 31, 2022
Dec 31, 2021